Richard Paulson

President and Chief Executive Officer, Karyopharm Therapeutics Inc.
,United States
Find Richard Paulson's Email
Find Richard Paulson's Phone

Who Is Richard Paulson?

Total Experience36 years
CompanyKaryopharm Therapeutics Inc.
CountryUnited States

Dr. Richard Paulson is a world-renowned reproductive endocrinologist and infertility specialist. He is a professor of obstetrics and gynecology and the former Director of the Division of Reproductive Endocrinology and Infertility at the University of Southern California's Keck School of Medicine. With a career spanning over three decades, Dr. Paulson is a leading authority on reproductive aging, oocyte donation, and the impact of hormones on the brain and behavior. His groundbreaking research has fundamentally changed the understanding of the limits of female reproductive potential, demonstrating that the age of the uterus is not a barrier to successful pregnancy. He is a past president of the American Society for Reproductive Medicine (ASRM) and has authored hundreds of scientific papers and book chapters, solidifying his reputation as a pivotal figure in modern reproductive medicine.

How Did Richard Paulson's Career Path Shape Their Journey?

Richard Paulson's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

Karyopharm Therapeutics Inc. - President and Chief Executive Officer(2021 to Present)
Ipsen - Chief Executive Officer, Ipsen North America(2018 to 2021)
Amgen - Vice President & General Manager Oncology, U.S. Oncology Business Unit(2015 to 2018)
Pfizer - CEO & Country Manager, Pfizer South Africa and Southern Africa(2005 to 2008)
Glaxo Wellcome, Canada, Inc. - Sales, Marketing & Market Access(1989 to 1999)

What Are Richard Paulson's Key Achievements?

Pioneering Research in Uterine Receptivity

Led groundbreaking research in the early 1990s demonstrating that the age-related decline in female fertility is due to the oocyte (egg) and not the uterus. This work proved that uteruses of postmenopausal women could successfully carry pregnancies with donor eggs, paving the way for oocyte donation as a standard treatment for age-related infertility.

Presidency of the American Society for Reproductive Medicine (ASRM)

Served as President of the ASRM from 2015 to 2016, the premier organization for professionals in reproductive medicine in the United States. His leadership role underscored his significant influence and standing within the global reproductive science community.

Landmark IVF Success in a 63-Year-Old Patient

Gained international recognition for reporting the successful pregnancy and delivery in a 63-year-old woman through IVF using a donor egg, which was the oldest successful pregnancy on record at the time. This case highlighted the clinical application of his research on uterine aging and pushed the boundaries of assisted reproductive technology.

What's Richard Paulson's Educational Background?

MBA, EMBA

University of Toronto - Rotman School of Management - Year 1994

Bachelor of Commerce - BCom, Marketing and Finance

University of Saskatchewan - Year 1986

Buying Intent Signals for Richard Paulson

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

Karyopharm Therapeutics Inc.
Total employees582
HeadquartersNewton
Founded2008

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel cancer therapies. The company is dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other major diseases. Karyopharm's lead compound, XPOVIO® (selinexor), is an oral Selective Inhibitor of Nuclear Export (SINE) compound approved in the U.S. for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Their core mission is to target the fundamental mechanisms of cancer to provide new treatment options for patients with high unmet medical needs.

Karyopharm Therapeutics Inc. Stock Information
Karyopharm Therapeutics Inc., Inc. is listed on the NASDAQ under the ticker symbol KPT. The company went public on November 6, 2013

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Thousands of companies, including, are just a search away.